Combretastatin A4

Catalog No.S7783

Combretastatin A4 Chemical Structure

Molecular Weight(MW): 316.35

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 M1zaVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWTDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDTT21GVC13IH3lcIFvd22jIHPlcIwhdGmwZYOsJGVFPTB;Mz6wNGUuODhizszN M1j2elE5PzV|NUC=
A-549 MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH\MXGREgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBCNTV2OTDseY5oKGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwMkDFMVA3KM7:TR?= MXKxPFc2OzVy
MCF-7 NE\NWINIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFHyR3dEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBOS0ZvNzDidoVie3RiY3HyZ4lvd22jIHPlcIwhdGmwZYOsJGVFPTB;Mz64NGUuODZizszN MoDaNVg4PTN3MB?=
HT-29 MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHXHOFlEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBJXC1{OTDjc4xwdiCjZHXuc4NiemOrbn;tZUBk\WyuIHzpcoV{NCCHREWwQVEvOjCHLUC2JO69VQ>? M2ixdFE5PzV|NUC=
MLM melanoma cell NEe5b2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEe5Wo5EgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBOVE1ibXXsZY5wdWFiY3XscEBtcW6nczygSWQ2OD1zLkSwSU0xPiEQvF2= MofTNVg4PTN3MB?=
M14 NGX6T3FEgXSxdH;4bYNqfHliYYPzZZk> NUXvcHV[UW5idnn0do8h[3m2b4TvfIlkKGGldHn2bZR6KHejczD0[ZN1\WRiYXfhbY5{fCCqdX3hckBu\Wyjbn;tZUBk[W6lZYKgLG0yPCliY3XscEBtcW6nLDDHTVUxRTBwMECwNUDPxE1? MXqxNlczQTZ2MB?=
SK-OV3 NUmyXo9zS3m2b4TvfIlkcXS7IHHzd4F6 NEOyRolKdiC4aYTyc{BkgXSxdH;4bYMh[WO2aY\peJkhfGW|dHXkJIFo[Wmwc4SgbJVu[W5ib4\hdolidiClYX7j[ZIhMFONLV;WN{kh[2WubDDsbY5mNCCJSUWwQVAvODByMTFOwG0> NYXjfGRKOTJ5Mkm2OFA>
HL60 cells NXm1ZWFbS3m2b4TvfIlkcXS7IHHzd4F6 MoqyO|IhcA>? MlTBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAxOSEQvF2= NYTwV2xHOjB5M{GzOVU>
SK-OV-3 M3\KRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnrYOFghcA>? MkS5S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2suV1ZvMzDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwNVMh|ryP NYDCU|RXOTh5MkKxNlc>
HepG2 cells MYfDfZRwfG:6aXPpeJkh[XO|YYm= NGXuUmhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyxiSVO1NF0xNjByMEG0JO69VQ>? NVfpZ2w6OTdzMkewOlE>
ZR-75-1 NXLMTnlkS3m2b4TvfIlkcXS7IHHzd4F6 M2LBR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KFqULUe1MVEh[2WubDDsbY5mNCCLQ{WwQVAvODByMkSg{txO MlHENVczPDl4NEm=
HeLa cell MX7DfZRwfG:6aXPpeJkh[XO|YYm= M1z1bmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEinTHGgZ4VtdCCuaX7lMEBKSzVyPUCuNFAxOyEQvF2= MYexO|I1QTZ2OR?=
HCT116 cell M1;6VmN6fG:2b4jpZ4l1gSCjc4PhfS=> NVr5bGtxS3m2b4TvfIlkcXS7IHHnZYlve3RiSFPUNVE3KGOnbHygcIlv\SxiSVO1NF0xNjByMEO1JO69VQ>? NVG3SoN7OTd{NEm2OFk>
KBV1 cells NF\6d5FEgXSxdH;4bYNqfHliYYPzZZk> MlrwO|IhcA>? M1XqcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJZqdmKuYYP0bY5mNXKnc3nzeIFvfCCNQm[xJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEC0JO69VQ>? Mn3kNlA4OzF|NUW=
SKOV3 M4rVS2N6fG:2b4jpZ4l1gSCjc4PhfS=> NFrMfIZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFA1OiEQvF2= M2C3blI1ODF4MECy
SKOV3 cells MlTDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFTBT45Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUU0:YMzDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwQVAvODByNEKg{txO MnvnNlM4PzJ|MEm=
HeLa cells M{PYTmN6fG:2b4jpZ4l1gSCjc4PhfS=> NGDQXXJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNFUyKM7:TR?= MWGxPVg4QTd3OB?=
DU145 cells NIThS2FEgXSxdH;4bYNqfHliYYPzZZk> NEK4OopEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFA2PCEQvF2= MViyOFAyPjByMh?=
DU145 cells Ml7TS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUCuNFAxPTRizszN NH7ve2EzOzd5MkOwPS=>
SK-N-BE M2T5ZnBzd2yrZnXyZZRqd25iYYPzZZk> M3PBTFczKGh? MljaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gV2suVi2ERTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODByNUig{txO NXSxcnpCOjJ|Mkm1OlE>
NCIH460 cells NEDUfXBEgXSxdH;4bYNqfHliYYPzZZk> NVfkVmVUPDhiaB?= MnHNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKUDR4MDDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODByNjFOwG0> MWKxPFMxOzh2OR?=
KB-VIN10 cells MkKxVJJwdGmoZYLheIlwdiCjc4PhfS=> M3S0blczKGh? MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuELW\JUlExKGOnbHzzJI93\XJvZYjwdoV{e2mwZzDQMYdxKDF5MD;NSHIyKGGodHXyJFczKGi{czDifUBu\XSqeXzlcoUh[my3ZTDhd5NigSxiSVO1NF0xNjByMEeg{txO MkPTNlE3PDF5MEC=
HCT116 cells NEHrTpdEgXSxdH;4bYNqfHliYYPzZZk> NUXhflA5PzJiaB?= MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC3NkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjByMEe0JO69VQ>? MnPwNlE6PTV2NUS=
DU145 cells M4e4ZWN6fG:2b4jpZ4l1gSCjc4PhfS=> Mmr5OFghcA>? NHi1RY9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODByODFOwG0> NXTObYltOTh|MEO4OFk>
RS4:11 cells MUjQdo9tcW[ncnH0bY9vKGG|c3H5 MlnGO|IhcA>? MlixRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCUU{S6NVEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IDizMUg1NDVvZHnt[ZRpgWy2aHnhfo9tNTJveXypMVItPS2maYDo[Y56dHSndILhfo9tcXWvIHLyc41q\GVidHXzeEwhUUN3ME2wMlAxODhizszN MX:yOVc5PTZyNR?=
HCT 116 MoXTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVTjZ4FxS2:wY3XueJJifGmxbjD3bIlkcCCycn;keYNmeyB3MDWgbY5pcWKrdHnvckBw\iCpcn;3eIghd2ZiaIXtZY4h[2:ub36geJVud3JiSFPUJFEyPixiSVO1NF0xNjByMEmg{txO MkTyNVE4OTR4MUO=
HeLa cells NGjIb5lEgXSxdH;4bYNqfHliYYPzZZk> NGO3c|E4OiCq M{HRZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJJme2G8dYLpckBj[XOnZDDmcJVwemW|Y3XuZ4Uh[XO|YYmsJGlEPTB;MD6wNFA6KM7:TR?= M2\kPFI1PjZ7OEi4
BNL 1ME A.7R.1 cells NE[zW4hEgXSxdH;4bYNqfHliYYPzZZk> NYr2O5I5S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSk6OIEHNSUBCNjeULkGgZ4VtdHNuIFnDOVA:OC5yMEC5JO69VQ>? MmK2NlU4QDV4MEW=
Calu6 MW\Qdo9tcW[ncnH0bY9vKGG|c3H5 MnLROFghcA>? NUjpUHoxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDZYx2PiCjZoTldkA1QCCqcoOgZpkhe3CnY4Tyc5Bpd3SxbXX0dpktKEmFNUC9NE4xODB7NDFOwG0> MYKyNVc4PDR7OR?=
melanoma B16 cell NYPJbnA2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M176SmNwdmOnboTyZZRqd25id3jpZ4gheHKxZIXj[ZMhPTBnIHnubIljcXSrb36gc4Yh\3Kxd4ToJI9nKG23cnnu[UBu\Wyjbn;tZUBDOTZiY3XscEBtcW6nLDDJR|UxRTBwMECxJO69VQ>? NED5Z4wyOTdzNE[xNy=>
DU145 cells NWH1dIpTS3m2b4TvfIlkcXS7IHHzd4F6 MmCzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? MV6yNFQ6Pjl{Mx?=
HCT116 cells MmP0VJJwdGmoZYLheIlwdiCjc4PhfS=> MXu3NkBp M2q0dmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NX\BNJRFOjFzMUKxN|A>
HCT15 cells MoLYVJJwdGmoZYLheIlwdiCjc4PhfS=> MUm3NkBp NXLaSFNYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= NXqwZWVvOjFzMUKxN|A>
HL60 cells M{j6[XBzd2yrZnXyZZRqd25iYYPzZZk> NYjENph6PzJiaB?= M4LR[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= M1vidlIyPjZ|M{G5
A10 cells MoHmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3z1S|Q5KGh? NGDEc2NIem:5dHigbY5pcWKrdHnvckBw\iC{YYSgRVExKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MV:yNlA1PDF4NB?=
HUVEC cells NUW0ZYY2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1j6XVQ5KGh? M4\2OWdzd3e2aDDpcohq[mm2aX;uJI9nKEiXVlXDJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO M1T5clIzODR2MU[0
HL60 cells MlzxR5l1d3SxeHnjbZR6KGG|c3H5 NX7FZZRyPzJiaB?= M3fGe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= MUKyNlE{PjNzMh?=
HL60 cells MYXQdo9tcW[ncnH0bY9vKGG|c3H5 NXvNZpVyPzJiaB?= NUnzXGRMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN MVuyNlU4QDFzMR?=
NCI-H522 cells NWfadno1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGX3[2Y1QCCq M{DBO2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUKyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO M3XmV|IzQTh{MUKy
MDA-MB-435 cells MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1fFU|Q5KGh? NYfuSnFiT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= Mny0NlI6QDJzMkK=
OVCAR3 Mom5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2XDVlQ5KGh? NEfVUmJIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBQXkODUkOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> NUnrVJJCOjJ7OEKxNlI>
NCI/ADR-RES cells NIXwVIlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWTx[FVVPDhiaB?= MVHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? MX6yNlk5OjF{Mh?=
PC3 cells M3fVRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3:0Z|Q5KGh? NV3ZPXU3T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN MWCyNlk5OjF{Mh?=
DU145 cells MnTJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXu0PEBp M3rxVmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN M3vLclIzQTh{MUKy
MDA-MB-231 cells NUf5cWtGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4HtXlQ5KGh? NYXmTnl{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= MkTnNlI6QDJzMkK=
CEM cells NEP2NWtEgXSxdH;4bYNqfHliYYPzZZk> NUDHO3VoPzJiaB?= MmrNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NFHTS|IzOjZ5NkK0Oy=>
HCT116 cells NXvVUoNbS3m2b4TvfIlkcXS7IHHzd4F6 NUjGZ|I3PzJiaB?= NIK3b5lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0> MVqyNlY4PjJ2Nx?=
MDA-MB-435 cells MVPDfZRwfG:6aXPpeJkh[XO|YYm= NVrzd4lbPzJiaB?= M2nENGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? M4G1VFIzPjd4MkS3
HaCaT cells M4f4NXBzd2yrZnXyZZRqd25iYYPzZZk> NV\xTVRFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIZWNiXCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO MXKyN|A3OzRyMR?=
HL60 cells NFvMVlNRem:uaX\ldoF1cW:wIHHzd4F6 NYXuRWpPPzJiaB?= MlP1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NEPieW4zOzFzN{G3NS=>
HL60 cells NVrXWVBEWHKxbHnm[ZJifGmxbjDhd5NigQ>? MYW3NkBp NUnBVW1[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTCoN{0pPCx3LXTpcYV1cHmudHjpZZpwdC1{LYnsLU0zNDVvZHnwbIVvgWy2ZYTyZZpwdGm3bTDido9ucWSnIITld5QtKEmFNUC9NE4xODFizszN MX6yOVc5PTZyNR?=
HT-29 NVmxbZVbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGDwZWtIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NGX2cWkzPTZ6OUGxNS=>
HL60 cells MXXQdo9tcW[ncnH0bY9vKGG|c3H5 M4LZelczKGh? M3XPPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? Mki0NlA1OjB2M{m=
Hs578T cells MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkjYOFghcA>? NXXo[nVST3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUHN3N{jUJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO Mn\wNlI6QDJzMkK=
HL60 cells NEK4ZXhEgXSxdH;4bYNqfHliYYPzZZk> NEfnSY84OiCq MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MlrlNlM1PDV2OU[=
SKOV3 cells NUHnXGh2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX3MOmU2T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= NYnjToJvOjV4OEmxNVE>
MDA-MB-468 cells NYm4TVVTS3m2b4TvfIlkcXS7IHHzd4F6 NYT4do1SPCCmYYnz Mnm1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxRTBwMECxNUDPxE1? NWnGR4U4OjR{MUC1NFM>
MCF7 cells NGnpUXFRem:uaX\ldoF1cW:wIHHzd4F6 MlnUO|IhcA>? MkLLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyOTFizszN NXPRN2VIOjJ|Mkm1OlE>
H460 NXLoXZFJS3m2b4TvfIlkcXS7IHHzd4F6 NYm0[nBQS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDR4MDDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIITld5QtKEmFNUC9NE4xODF{IN88US=> MYSxPFc5OzJyNx?=
H460 MX;Qdo9tcW[ncnH0bY9vKGG|c3H5 MnjPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKNE[wJINmdGy|LDDJR|UxRTBwMECxNlQh|ryP M{nBPVE3PzJ{NkOz
NCI-H460 cells NYT3NWxYS3m2b4TvfIlkcXS7IHHzd4F6 Mkj1O|IhcA>? NWrOb3NpS3m2b4TvfIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIhfGW|dDygTWM2OD1yLkCwNVMh|ryP MYCxPFM6Pjh3Nx?=
OVCAR8 cells MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYPKXZFpQTZiaB?= MY\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDPWmNCWjhiY3XscJMhd3[ncnX4dJJme3OrbnegVE1odHmlb4Dyc5RmcW5iYX\0[ZIhQTZiaILzMEBKSzVyPUCuNFAyOyEQvF2= MWGyNlA1PDF4NB?=
NCI/ADR-RES cells MUHDfZRwfG:6aXPpeJkh[XO|YYm= MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBjgSC2conwZY4h[my3ZTDlfINtfXOrb36gZZN{[XluIFnDOVA:OC5yMEGzJO69VQ>? MlvNNlMzOTR2NUK=
OVCAR8 cells MXnDfZRwfG:6aXPpeJkh[XO|YYm= MmDXPVYhcA>? MlO1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDl4IHjyd{BjgSCJaXXtd4Ehe3SjaX7pcocu[mG|ZXSgcIlocHRibXnjdo9{[2:yeTygTWM2OD1yLkCwNVMh|ryP M3\PVVI2ODJ3OUmx
NCI/ADR-RES cells Ml3nR5l1d3SxeHnjbZR6KGG|c3H5 MXy5OkBp NU\1T|RrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLL1HEVk1TTVNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhQTZiaILzJIJ6KEerZX3zZUB{fGGrbnnu[{1j[XOnZDDsbYdpfCCvaXPyc5Nkd3C7LDDJR|UxRTBwMECxN{DPxE1? M1m1V|I2ODJ3OUmx
OVCAR8 cells NGTwSHlEgXSxdH;4bYNqfHliYYPzZZk> M3\Z[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUODDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDifUB1enmyYX6gZox2\SCneHPseZNqd25iYYPzZZktKEmFNUC9NE4xODF|IN88US=> NXrm[YllOjN{MUS0OVI>
HuTu 80 cells NVT0OmdbWHKxbHnm[ZJifGmxbjDhd5NigQ>? NVvGV2hPPzJiaB?= MoLPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gTJVVfSB6MDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzM{eg{txO NVjDS4VtOjJ|Mkm1OlE>
K562 cells MXTDfZRwfG:6aXPpeJkh[XO|YYm= M4TlTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMtKEmFNUC9NE4xODF2IN88US=> MY[xPVg{PzV7NB?=
NCI/ADR (MDR) cells NFHR[ppHfW6ldHnvckBie3OjeR?= NWL4WJVkS2WubDDjfYNt\SCjcoLld5QhcW5iTlPJM2FFWiBqTVTSLUBk\WyuczDifUBi[2O3bYXsZZRqd25iYYSgS|IwVSCyaHHz[UwhUUN3ME2wMlAxOTVizszN MlS4NVY{PzdzOEe=
HUVEC MUDQdo9tcW[ncnH0bY9vKGG|c3H5 Ml7VRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVW\FR{whUUN3ME2wMlAxOTVizszN NGPmeHAyPjd{Mk[zNy=>
KB cell MWTQdo9tcW[ncnH0bY9vKGG|c3H5 NH7pfI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCJINmdGxibHnu[UBjgSCvZYTofYxmdmViYnz1[UBlgWViYYPzZZktKEmFNUC9NE4xODF3IN88US=> NH7pbXIyPzB|NEG0Oy=>
KB-VIN10 cell MknUVJJwdGmoZYLheIlwdiCjc4PhfS=> Mm\qRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNQj3WTW4yOCClZXzsJIxqdmViYomgcYV1cHmuZX7lJIJtfWViZInlJIF{e2G7LDDJR|UxRTBwMECxOUDPxE1? MnfONVcxOzRzNEe=
Human SH-SY5Y neuroblastoma cells MkLZSpVv[3Srb36gZZN{[Xl? MUjJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCKdX3hckBUUC2VWUXZJI5mfXKxYnzhd5RwdWFiY3XscJMtKEmFNUC9NE4xODF3IN88US=> NVrRdWFuOTV7NkO3NlI>
SW620 cells NUHSV5hOWHKxbHnm[ZJifGmxbjDhd5NigQ>? M4L0[|czKGh? NEjER5RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBqdiCqdX3hckBUXzZ{MDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzNUKg{txO MVSyNlMzQTV4MR?=
Molt4/C8 cells M3vJfXBzd2yrZnXyZZRqd25iYYPzZZk> MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2xbIS0M2M5KGOnbHzzMEBKSzVyPUCuNFAyPiEQvF2= NX\kWGVIOTdyM{SxOVA>
ACHN cell NYP5e5BjWHKxbHnm[ZJifGmxbjDhd5NigQ>? NXOybFNjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBlenWpIILld4l{fGGwdDDBR2hPKGOnbHygcIlv\SCneIDy[ZN{cW6pIF3EVlEh[nliQXzhcYFzKEKudXWgZZN{[XluIFnDOVA:OC5yMEG2JO69VQ>? Mm\uNVczQDZ|OUO=
Molt4/C8 cells MlvzVJJwdGmoZYLheIlwdiCjc4PhfS=> MlXqN{Bl[Xm| Ml;uRY51cXC{b3zp[oVz[XSrdnWg[YZn\WO2IHHnZYlve3RiaIXtZY4hVW:udESvR|gh[2WubIOgZYZ1\XJiMzDkZZl{NCCLQ{WwQVAvODBzNjFOwG0> NITycIsyPzRzOU[wOy=>

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
+ Expand

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
+ Expand
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Formulation: DMSO
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID